Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers

Robert M. Post, Lori L. Altshuler, Mark A Frye, Trisha Suppes, A. John Rush, Paul E. Keck, Susan L. McElroy, Kirk D. Denicoff, Gabriele S. Leverich, Ralph Kupka, Willem A. Nolen

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Introduction: Bipolar patients with breakthrough major depressive episodes despite ongoing adequately-dosed mood stabilizer medication were randomized in a double-blind manner to one of three antidepressants with different mechanisms of action: bupropion, sertraline, or venlafaxine. Preliminary data are presented on the switch rates into hypomania or mania for the antidepressants as a group prior to unblinding the specific individual drug efficacy and tolerability data in this ongoing clinical trial. Methods: Subjects included 64 bipolar patients who participated at five sites in a 10-week double-blind trial for depression and a 1-year blinded continuation maintenance phase for responders. Nonresponders were re-randomized such that there were 95 acute treatment phases. In the acute phase, doses were titrated to clinical response, side effects, or maximum dose of bupropion (450 mg/day), sertraline (200 mg/day), or venlafaxine (375 mg/day). Daily ratings on the National Institute of Mental Health-Life Chart Methodology (NIMH-LCM) were inspected for the degree of improvement on the Clinical Global Impressions scale as revised for bipolar illness (CGI-BP) and the occurrence of hypomania or mania. Results: Thirty-five (37%) of the 95 acute treatment phases were associated with a much or very much improved rating in depression on the CGI-BP. Thirteen (14%) of these 95 acute trials of antidepressants as adjuncts to mood stabilizers were associated with switches, seven into hypomania and six into mania. Forty-two patients elected to go into the continuation phase in 48 instances. Sixteen (33%) of the continuation phase trials were associated with mood switches, 10 into hypomania and six into mania. Conclusions: In this randomized double-blind prospective study of three second-generation antidepressants (bupropion, sertraline, and venlafaxine) in bipolar patients whose depression broke through ongoing treatment with mood stabilizers, switches into hypomania or mania occurred in 14% of the acute phases and 33% of the continuation phases. Individual data on each drug will be assessed in the next phase of the study after more subjects are recruited and the blind is broken.

Original languageEnglish (US)
Pages (from-to)259-265
Number of pages7
JournalBipolar Disorders
Volume3
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Bipolar Disorder
Antidepressive Agents
Bupropion
Sertraline
Depression
National Institute of Mental Health (U.S.)
Double-Blind Method
Pharmaceutical Preparations
Therapeutics
Maintenance
Clinical Trials
Prospective Studies
Venlafaxine Hydrochloride

Keywords

  • Antidepressants
  • Bipolar
  • Bupropion
  • Controlled trial
  • Depression
  • Hypomania
  • Mania
  • Sertraline
  • Switching
  • Venlafaxine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology

Cite this

Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. / Post, Robert M.; Altshuler, Lori L.; Frye, Mark A; Suppes, Trisha; Rush, A. John; Keck, Paul E.; McElroy, Susan L.; Denicoff, Kirk D.; Leverich, Gabriele S.; Kupka, Ralph; Nolen, Willem A.

In: Bipolar Disorders, Vol. 3, No. 5, 2001, p. 259-265.

Research output: Contribution to journalArticle

Post, RM, Altshuler, LL, Frye, MA, Suppes, T, Rush, AJ, Keck, PE, McElroy, SL, Denicoff, KD, Leverich, GS, Kupka, R & Nolen, WA 2001, 'Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers', Bipolar Disorders, vol. 3, no. 5, pp. 259-265. https://doi.org/10.1034/j.1399-5618.2001.030505.x
Post, Robert M. ; Altshuler, Lori L. ; Frye, Mark A ; Suppes, Trisha ; Rush, A. John ; Keck, Paul E. ; McElroy, Susan L. ; Denicoff, Kirk D. ; Leverich, Gabriele S. ; Kupka, Ralph ; Nolen, Willem A. / Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. In: Bipolar Disorders. 2001 ; Vol. 3, No. 5. pp. 259-265.
@article{0c3a9a00303941488f16d2dfd07fccc3,
title = "Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers",
abstract = "Introduction: Bipolar patients with breakthrough major depressive episodes despite ongoing adequately-dosed mood stabilizer medication were randomized in a double-blind manner to one of three antidepressants with different mechanisms of action: bupropion, sertraline, or venlafaxine. Preliminary data are presented on the switch rates into hypomania or mania for the antidepressants as a group prior to unblinding the specific individual drug efficacy and tolerability data in this ongoing clinical trial. Methods: Subjects included 64 bipolar patients who participated at five sites in a 10-week double-blind trial for depression and a 1-year blinded continuation maintenance phase for responders. Nonresponders were re-randomized such that there were 95 acute treatment phases. In the acute phase, doses were titrated to clinical response, side effects, or maximum dose of bupropion (450 mg/day), sertraline (200 mg/day), or venlafaxine (375 mg/day). Daily ratings on the National Institute of Mental Health-Life Chart Methodology (NIMH-LCM) were inspected for the degree of improvement on the Clinical Global Impressions scale as revised for bipolar illness (CGI-BP) and the occurrence of hypomania or mania. Results: Thirty-five (37{\%}) of the 95 acute treatment phases were associated with a much or very much improved rating in depression on the CGI-BP. Thirteen (14{\%}) of these 95 acute trials of antidepressants as adjuncts to mood stabilizers were associated with switches, seven into hypomania and six into mania. Forty-two patients elected to go into the continuation phase in 48 instances. Sixteen (33{\%}) of the continuation phase trials were associated with mood switches, 10 into hypomania and six into mania. Conclusions: In this randomized double-blind prospective study of three second-generation antidepressants (bupropion, sertraline, and venlafaxine) in bipolar patients whose depression broke through ongoing treatment with mood stabilizers, switches into hypomania or mania occurred in 14{\%} of the acute phases and 33{\%} of the continuation phases. Individual data on each drug will be assessed in the next phase of the study after more subjects are recruited and the blind is broken.",
keywords = "Antidepressants, Bipolar, Bupropion, Controlled trial, Depression, Hypomania, Mania, Sertraline, Switching, Venlafaxine",
author = "Post, {Robert M.} and Altshuler, {Lori L.} and Frye, {Mark A} and Trisha Suppes and Rush, {A. John} and Keck, {Paul E.} and McElroy, {Susan L.} and Denicoff, {Kirk D.} and Leverich, {Gabriele S.} and Ralph Kupka and Nolen, {Willem A.}",
year = "2001",
doi = "10.1034/j.1399-5618.2001.030505.x",
language = "English (US)",
volume = "3",
pages = "259--265",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",
number = "5",

}

TY - JOUR

T1 - Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers

AU - Post, Robert M.

AU - Altshuler, Lori L.

AU - Frye, Mark A

AU - Suppes, Trisha

AU - Rush, A. John

AU - Keck, Paul E.

AU - McElroy, Susan L.

AU - Denicoff, Kirk D.

AU - Leverich, Gabriele S.

AU - Kupka, Ralph

AU - Nolen, Willem A.

PY - 2001

Y1 - 2001

N2 - Introduction: Bipolar patients with breakthrough major depressive episodes despite ongoing adequately-dosed mood stabilizer medication were randomized in a double-blind manner to one of three antidepressants with different mechanisms of action: bupropion, sertraline, or venlafaxine. Preliminary data are presented on the switch rates into hypomania or mania for the antidepressants as a group prior to unblinding the specific individual drug efficacy and tolerability data in this ongoing clinical trial. Methods: Subjects included 64 bipolar patients who participated at five sites in a 10-week double-blind trial for depression and a 1-year blinded continuation maintenance phase for responders. Nonresponders were re-randomized such that there were 95 acute treatment phases. In the acute phase, doses were titrated to clinical response, side effects, or maximum dose of bupropion (450 mg/day), sertraline (200 mg/day), or venlafaxine (375 mg/day). Daily ratings on the National Institute of Mental Health-Life Chart Methodology (NIMH-LCM) were inspected for the degree of improvement on the Clinical Global Impressions scale as revised for bipolar illness (CGI-BP) and the occurrence of hypomania or mania. Results: Thirty-five (37%) of the 95 acute treatment phases were associated with a much or very much improved rating in depression on the CGI-BP. Thirteen (14%) of these 95 acute trials of antidepressants as adjuncts to mood stabilizers were associated with switches, seven into hypomania and six into mania. Forty-two patients elected to go into the continuation phase in 48 instances. Sixteen (33%) of the continuation phase trials were associated with mood switches, 10 into hypomania and six into mania. Conclusions: In this randomized double-blind prospective study of three second-generation antidepressants (bupropion, sertraline, and venlafaxine) in bipolar patients whose depression broke through ongoing treatment with mood stabilizers, switches into hypomania or mania occurred in 14% of the acute phases and 33% of the continuation phases. Individual data on each drug will be assessed in the next phase of the study after more subjects are recruited and the blind is broken.

AB - Introduction: Bipolar patients with breakthrough major depressive episodes despite ongoing adequately-dosed mood stabilizer medication were randomized in a double-blind manner to one of three antidepressants with different mechanisms of action: bupropion, sertraline, or venlafaxine. Preliminary data are presented on the switch rates into hypomania or mania for the antidepressants as a group prior to unblinding the specific individual drug efficacy and tolerability data in this ongoing clinical trial. Methods: Subjects included 64 bipolar patients who participated at five sites in a 10-week double-blind trial for depression and a 1-year blinded continuation maintenance phase for responders. Nonresponders were re-randomized such that there were 95 acute treatment phases. In the acute phase, doses were titrated to clinical response, side effects, or maximum dose of bupropion (450 mg/day), sertraline (200 mg/day), or venlafaxine (375 mg/day). Daily ratings on the National Institute of Mental Health-Life Chart Methodology (NIMH-LCM) were inspected for the degree of improvement on the Clinical Global Impressions scale as revised for bipolar illness (CGI-BP) and the occurrence of hypomania or mania. Results: Thirty-five (37%) of the 95 acute treatment phases were associated with a much or very much improved rating in depression on the CGI-BP. Thirteen (14%) of these 95 acute trials of antidepressants as adjuncts to mood stabilizers were associated with switches, seven into hypomania and six into mania. Forty-two patients elected to go into the continuation phase in 48 instances. Sixteen (33%) of the continuation phase trials were associated with mood switches, 10 into hypomania and six into mania. Conclusions: In this randomized double-blind prospective study of three second-generation antidepressants (bupropion, sertraline, and venlafaxine) in bipolar patients whose depression broke through ongoing treatment with mood stabilizers, switches into hypomania or mania occurred in 14% of the acute phases and 33% of the continuation phases. Individual data on each drug will be assessed in the next phase of the study after more subjects are recruited and the blind is broken.

KW - Antidepressants

KW - Bipolar

KW - Bupropion

KW - Controlled trial

KW - Depression

KW - Hypomania

KW - Mania

KW - Sertraline

KW - Switching

KW - Venlafaxine

UR - http://www.scopus.com/inward/record.url?scp=0034775032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034775032&partnerID=8YFLogxK

U2 - 10.1034/j.1399-5618.2001.030505.x

DO - 10.1034/j.1399-5618.2001.030505.x

M3 - Article

VL - 3

SP - 259

EP - 265

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

IS - 5

ER -